glp-1 insurance changes CMS Issues Coverage Guidance on Anti-Obesity Drugs GLP-1 insurance change impacts millions

The authors observed a dose-dependent body weight reduction of up to 16.9% with retatrutide (12 mg escalating group) at 36 weeks, which did not appear to have plateaued at 36 weeks, versus 3.0% with the placebo and 2% with 1.5 mg dulaglutide

Blonde L, Berard L, Saremi A, Huang Y, Aroda VR, Raccah D

Especially if they dont like taking injections, its easier to administer and take

We often argue in these pages for the value of supporting basic biological research-research done to understand how the body works rather than to achieve a specific health goal

Insurance formulary preferences vary by plan and may favor one medication over the other